Press release

 

Heart failure: a new cellular therapeutic pathway

Paris, December 3, 2002

 

Following a heart attack, millions of cells that provide contractile function to the heart are destroyed. By transplanting embryonic stem cells in the postinfarction hearts of rats, a CNRS research team succeeded in directing the differentiation of cells into cardiomyocytes or heart cells. The experiment revealed perfect tolerance by the host animal and recovery of heart function. Although much work remains to be done, particularly on human embryonic stem cells, these results present an alternative to transplants of the myocardium that involve major surgery. The experiment was carried out by the "ES(1) and heart differentiation cell" team, under the supervision of Michel Pucéat, at the CNRS Macromolecular Biochemistry Research Center(2) , working in partnership with André Terzic's team at the MAYO(3) Clinic (Minnesota, United States).

Heart failure is one of the consequences of many different types of heart disease (myocardial infarction, high blood pressure, increased blood cholesterol level, cardiomyopathy, etc.). It affects thousands of French people and is responsible for a very large part of the mortality rate. 176,000 people die every year of cardiovascular disease in France(4) . Due to the lack of adequate drug treatment, this pathology most often results in a heart transplant. However, patients must undergo major surgery and are required to follow a restrictive anti-rejection treatment with dangerous long-term side effects. Moreover, not all patients (diabetics, for example) qualify for a transplant. Finally, the number of donors remains considerably limited and cannot meet the present demand for transplants in our country.

The heart is made up of about two billion cells, each one forming a contractile unit. These cells all contract together, keeping the heart pump going. When a heart attack occurs, millions of cells are lost because the heart is an organ that does not have the capacity to regenerate itself. The resulting loss of mechanical function of the myocardium is responsible for the failure, which develops over the years following infarction. Grafting of embryonic stem cells that have the potential to generate all types of tissues and whose purpose could be predetermined, can also replace areas destroyed during a heart attack.

A new "cellular" therapeutic pathway
Researchers have recently discovered that the myocardium in animals is a propitious site for transplanting embryonic stem cells that, by spontaneously differentiating into heart cells, lead to the total recovery of mechanical function. By using differentiation factors naturally present in the healthy or postinfarction myocardium, they have shown that it is possible to direct the differentiation of murine embryonic stem cells into cardiomyocytes. When transplanted in vivo in infarcted rat myocardium following an experimentally induced heart attack, stem cells spontaneously differentiated into cardiomyocytes. By experimentally blocking the activation of the cell receptors in these differentiation factors, both in vitro and in vivo, stem cells are no longer capable of differentiating but, on the contrary, proliferate in a non-differentiated state.
Researchers have thus shown that these same endogenous growth factors are responsible for the spontaneous differentiation of stem cells in the myocardium.

The transplanting of stem cells makes it possible to restock the ischaemic (lacking in oxygen) and fibrotic areas of the postinfarction heart and leads to total recovery of mechanical function (of the pump) of the unhealthy myocardium, with no sign of rejection of the grafted cells. Stem cells were not even rejected eight months following heterologous grafts(5) , demonstrating perfect tolerance by the host animal.

Although much work remains to be done, particularly on human embryonic stem cells, these results offer a real possibility for cell therapy for heart failure in humans.

This research, financed by the French Myopathy Association and the Foundation of France was published on October 1st 2002 in the FASEB Journal (volume 16, pp. 1558-1566), the journal of the Federation of American Societies for Experimental Biology ("Stem cell differentiation requires a paracrine pathway in the heart", by Atta Behfar, Leonid V. Zingman, Denice M. Hodgson, Jean-Michel Rauzier, Garvan C. Kane, André Terzic, Michel Pucéat).

(1)ES for embryonic stem
(2)The Macromolecular Biochemistry Research Center directed by Marcel DOREE was created in 1998 and includes 96 people of whom 41 are professional researchers (CNRS, INSERM, university-affiliated), in Montpellier. Its research activities are open to the public through contractual relationships and partnerships with public and private organisations. http://xerxes.crbm.cnrs-mop.fr/present.html
(3)The MAYO Clinic is one of the largest hospital research centers in the United States and the first in cardiology.
(4)Source: INSERM 2000
(5)Heterologous graft: from one species to another, in this case, the cells of mice introduced into the rat.


Researcher contact:
Michel Pucéat
Centre de Recherches de Biochimie Macromoléculaire
Tel: +33 4 67 61 34 32
puceat@crbm.cnrs-mop.fr

Press contact:
Nathalie Tramunt
Tel : +33 1 44 96 46 06